Windward Bio Group AG Common Shares (WWB) stock forecast & analysis
28.50
NasdaqGS · USDDelayed by 15 minutes
Up: +11.50, +67.6%
1 analysis
Latest analysis: · verdict locked
- Open
- 18.35
- Previous close
- 17.00
- Day range
- 18.35 – 33.99
- 52-week range
- 18.35 – 33.99
- Volume (shares)
- 1.28M
- Net assets
- Not available
- Expense ratio
- Not available
- Shares outstanding
- 58.04M
- P/E ratio
- Not available
- Dividend yield
- 0.00%
- Beta
- Not available
- Market cap
- 1.65B
Market Scanner’s AI analysis of Windward Bio Group AG Common Shares (WWB), updated November 2026: WWB's recent analyses focused on its biotechnology operations and financial health, with limited market data available.
This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Windward Bio Group AG Common Shares (WWB) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.
Summary
WWB's recent analyses focused on its biotechnology operations and financial health, with limited market data available.
Recent analyses for WWB, operating in the Biotechnology industry, examined its financial standing as of June 30, 2026. The reports noted the company's market capitalization, stock price, and key financial metrics including profitability and liquidity. However, limited news and technical data prevented a broader market or trading trend analysis.
Fundamentals
The company's profitability was negative, with losses reported in earnings per share, operating income, and net income. However, its liquidity position was strong, characterized by a high current ratio and quick ratio, with substantial cash reserves relative to its debt.
Factors discussed — upside
- Strong short-term liquidity indicated by a Current Ratio of 8.571 and Quick Ratio of 8.494.
- Total Cash of $186,467,008 USD significantly exceeds Total Debt of $474,000 USD.
Factors discussed — risks
- Reported negative Earnings Per Share (EPS) of -0.83 USD.
- Operating income and net income were negative for the fiscal year ending December 31, 2025.
- Financial Health
- Liquidity
- Profitability
- Biotechnology Industry
Summary updated .
Analyses
Recent WWB.US analyses are locked — sign in to read them or generate a fresh one.
Locked
Unlock in the library — 1 newer report
Sign in to unlock the 2026-11-16 WWB.US analysis
Get the verdict — free
Frequently asked questions
- What is the bull case for Windward Bio Group AG Common Shares?
- The company's strong short-term liquidity is a key positive, underscored by a Current Ratio of 8.571 and a Quick Ratio of 8.494. Additionally, its substantial cash reserves of $186,467,008 USD far exceed its total debt of $474,000 USD.
- What are the risks for Windward Bio Group AG Common Shares?
- The company has faced profitability challenges, as indicated by a negative Earnings Per Share (EPS) of -0.83 USD. Furthermore, its operating income and net income were negative for the fiscal year ending December 31, 2025.
- Is Windward Bio Group AG Common Shares bullish or bearish?
- Recent AI analyses of Windward Bio Group AG Common Shares examined factors on both sides. Discussed upside: The company's strong short-term liquidity is a key positive, underscored by a Current Ratio of 8.571 and a Quick Ratio of 8.494. Additionally, its substantial cash reserves of $186,467,008 USD far exceed its total debt of $474,000 USD. Discussed risks: The company has faced profitability challenges, as indicated by a negative Earnings Per Share (EPS) of -0.83 USD. Furthermore, its operating income and net income were negative for the fiscal year ending December 31, 2025. These are descriptive observations, not a recommendation.
- What is the latest sentiment on Windward Bio Group AG Common Shares?
- Recent analyses for WWB, operating in the Biotechnology industry, examined its financial standing as of June 30, 2026. The reports noted the company's market capitalization, stock price, and key financial metrics including profitability and liquidity. However, limited news and technical data prevented a broader market or trading trend analysis.
- How does Market Scanner analyse Windward Bio Group AG Common Shares?
- Every analysis of Windward Bio Group AG Common Shares runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology
What is the bull case for Windward Bio Group AG Common Shares?
The company's strong short-term liquidity is a key positive, underscored by a Current Ratio of 8.571 and a Quick Ratio of 8.494. Additionally, its substantial cash reserves of $186,467,008 USD far exceed its total debt of $474,000 USD.
What are the risks for Windward Bio Group AG Common Shares?
The company has faced profitability challenges, as indicated by a negative Earnings Per Share (EPS) of -0.83 USD. Furthermore, its operating income and net income were negative for the fiscal year ending December 31, 2025.
Is Windward Bio Group AG Common Shares bullish or bearish?
Recent AI analyses of Windward Bio Group AG Common Shares examined factors on both sides. Discussed upside: The company's strong short-term liquidity is a key positive, underscored by a Current Ratio of 8.571 and a Quick Ratio of 8.494. Additionally, its substantial cash reserves of $186,467,008 USD far exceed its total debt of $474,000 USD. Discussed risks: The company has faced profitability challenges, as indicated by a negative Earnings Per Share (EPS) of -0.83 USD. Furthermore, its operating income and net income were negative for the fiscal year ending December 31, 2025. These are descriptive observations, not a recommendation.
What is the latest sentiment on Windward Bio Group AG Common Shares?
Recent analyses for WWB, operating in the Biotechnology industry, examined its financial standing as of June 30, 2026. The reports noted the company's market capitalization, stock price, and key financial metrics including profitability and liquidity. However, limited news and technical data prevented a broader market or trading trend analysis.
How does Market Scanner analyse Windward Bio Group AG Common Shares?
Every analysis of Windward Bio Group AG Common Shares runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.
Read the methodology- Bundles used
- gemini-low-v2
Run a fresh WWB.US analysis
Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.